Ascentage Pharma Group International (HKG:6855)
Hong Kong · Delayed Price · Currency is HKD 72.70
-1.80 (-2.42%)
Sep 26, 2025, 4:08 PM HKT
HKG:6855 Revenue
Ascentage Pharma Group International had revenue of 233.70M CNY in the half year ending June 30, 2025, with 63.77% growth. This brings the company's revenue in the last twelve months to 390.60M, down -56.75% year-over-year. In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M with 341.77% growth.
Revenue (ttm)
390.60M CNY
Revenue Growth
-56.75%
P/S Ratio
62.40
Revenue / Employee
688.89K CNY
Employees
567
Market Cap
26.71B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 35.81B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
Ascentage Pharma Group International News
- 25 days ago - Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 weeks ago - Ascentage Pharma Group International GAAP EPS of -$0.24, revenue of $32.6M - Seeking Alpha
- 5 weeks ago - Ascentage Pharma Group International (AAPG) Advances in Global Phase III Study for Higher-Risk ... - GuruFocus
- 2 months ago - Ascentage Pharma Group International Announces Key Executive Appointments | AAPG stock news - GuruFocus
- 6 months ago - Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan - Benzinga
- 6 months ago - Earnings Scheduled For March 27, 2025 - Benzinga
- 6 months ago - Ascentage Pharma Group International (AAPG) Showcases Innovative Cancer Therapies at AACR 2025 - GuruFocus
- 8 months ago - Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO - Reuters